Voyager Therapeutics, Inc. Overview
Pro stress-test →Voyager Therapeutics is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Its pipeline includes programs for Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system.
Strategic Profile
Pro stress-test →The company's TRACER™ AAV capsid discovery platform has been used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Programs are advanced through a mix of wholly owned assets and collaborations with partners including Neurocrine, Novartis, Alexion and Transition Bio, with cash runway into 2028 based on current plans and collaboration reimbursements.
Competitive Landscape
Pro stress-test →Voyager focuses on neurogenetic medicines for CNS disorders, leveraging gene therapy, antibodies, its TRACER capsid discovery platform, and emerging non-viral and small-molecule approaches. Key competitor areas include other tau-targeting programs (Biogen's BIIB080), gene therapy platforms (Solid Biosciences, REGENXBIO), and small-molecule CNS companies.
Industry Context
Voyager Therapeutics, Inc. operates in Biotechnology - Gene Therapy / Neurological Therapeutics.
Key facts
Headquarters: Lexington, Massachusetts · Revenue: $13.4M · Market cap: $222M